Video Preview
🎧 Podcast episode for paid subscribers only. Also available on Apple Podcasts and Spotify.
To listen to paid episodes in Apple or Spotify, link your Substack subscription via the show settings on those platforms (instructions inside the Substack app under Subscriptions → Podcast).
Abstract
Q3 2026 (July 1 to Sept 30) produced the usual pile of commercial payer bulletins. Five changes from that pile get sorted here by one test, whether the change supports a new company or just hands an existing vendor a feature. Two add a clinical indication that wasn’t covered before and three change how existing care gets authorized or paid. None is a mandate, so all five are payer-policy tailwinds and nothing sturdier.
UHC commercial, effective Oct 1. Tzield for recently diagnosed stage 3 T1D, with at least one positive pancreatic islet cell autoantibody and peak C-peptide of at least 0.2 pmol/mL, max two 12-dose courses per lifetime. The bulletin does not limit this pathway to ages 8 to 17. The FDA indication remains stage 2 T1D in adults and children aged 1 year or older; UHC’s new policy language separately addresses stage 3 T1D.
Cigna policy 0528, effective Nov 15. LITT for newly diagnosed glioblastoma or other glioma, with the lesion cap moving from 30 cc of volume to 3 cm of diameter (about 14 cc).
UHC site of care, effective Oct 1. Seven products added to the list, four of them twice-a-year subQ shots.
Elevance, announced Sept 29. Physical location on hospital claims plus off-campus rates, rolling out across 2026 and 2027, ahead of a federal off-campus NPI and attestation deadline of Jan 1, 2028.
Georgia gold cards, live since July 1. Fully insured plans mostly, with Aetna, UHC and Anthem each running a different rulebook.
Verdict. Tzield ops first for a clinical-services team, Elevance location data first for a software team, and the other three are features.
Table of Contents
Why anyone should read payer bulletins
The Tzield pathway and the eight week clock
What the Tzield math looks like
LITT for new gliomas, with a geometry problem
Site of care and the seven new names on the list
Elevance wants to know where the building is
Georgia gold cards and three different rulebooks
The prior auth bot problem and other leftovers
Ranking the five and what would change the order
Why anyone should read payer bulletins
Payer policy bulletins are the least loved documents in healthcare, and that’s in a field that includes EOBs. UHC’s September commercial bulletin runs 32 pages, most of it tables where the left column says what changed and the right column reprints the entire policy in case anyone missed it. Cigna’s August update manages to cover breast reduction after GLP-1 weight loss, photopheresis, Alzheimer’s antibodies and the step therapy ladder for Xeljanz in one PDF. Nobody reads these for fun. Billing managers skim for their own specialty, and founders mostly learn what was in them when a customer calls to say the product broke. That’s a waste, bc the bulletins are where reimbursement actually moves. An FDA approval says a drug can be sold. A line in a medical policy says one payer will cover it for a kid with specific lab values starting on a specific date, and that second document is the one a business can be planned around. It also shows up with zero press coverage a few months after the first.
The quarter that ended Sept 30 had at least five changes worth a look, and they split into two bins. Two of them add a clinical indication that wasn’t covered before. The other three change how existing care gets authorized or paid. A new company might fit in the first bin. The second bin is mostly where an existing vendor ships a feature and sends a product update email. Several of the five were announced in Q3 but don’t take effect until October or November, so the window to do something about them is open right now. One caveat before the details, since this audience will ask. None of the five is a mandate. No broad final federal or state coverage requirement turned up in the quarter’s output, and not finding one in a stack of PDFs doesn’t prove there isn’t one. These are commercial payers editing their own rules, so each rule covers only that payer’s book and bends to plan documents and employer choices. It can also be edited again next quarter. A coverage policy isn’t a promise to pay either (every bulletin says so in the fine print, usually twice). The rankings further down are judgment calls from reading documents, and no customer has been asked what they’d pay for any of it.
